Losing Weight on Semaglutide: Clinical Evidence, Realistic Expectations, and Practical Guidance

Semaglutide at 2.4mg weekly (branded Wegovy in the UK) represents one of the most significant advances in pharmaceutical weight management in decades. The clinical trial data substantially exceeds previous pharmacological options, and the mechanism is well-understood. This article covers the evidence, realistic expectations based on published trial data, side effects, the UK prescribing pathway, and the lifestyle factors that determine long-term outcomes.

What Semaglutide Is

Semaglutide is a GLP-1 receptor agonist — a synthetic analogue of glucagon-like peptide-1, a hormone naturally produced in the gut after eating. It was originally developed as a diabetes medication (at 0.5–1mg weekly as Ozempic) and subsequently trialled at higher doses (2.4mg weekly) specifically for weight management in people without diabetes.

The 2.4mg weekly formulation (Wegovy) received NICE approval in the UK in 2023 for chronic weight management. A lower dose (1mg weekly as Ozempic) is approved for type 2 diabetes.

Key distinction: Ozempic (1mg) and Wegovy (2.4mg) contain the same active ingredient at different doses for different indications. Using Ozempic off-label for weight management at doses outside the licensed diabetes indication is not equivalent to the Wegovy evidence base.

Mechanism of Action

Semaglutide acts on GLP-1 receptors throughout the body:

Hypothalamic appetite regulation: GLP-1 receptors in the hypothalamus (specifically the arcuate nucleus) signal satiety. Semaglutide's extended half-life (approximately 7 days, allowing weekly dosing) provides sustained activation of these receptors, reducing appetite signals throughout the week.

Gastric emptying slowing: GLP-1 receptors in the stomach slow gastric motility, extending the period over which food moves from the stomach to the small intestine. This prolongs the post-meal satiety period and reduces calorie absorption rate.

Reward pathway modulation: Emerging evidence suggests semaglutide also acts on the mesolimbic dopamine system — reducing food reward salience. In clinical practice, patients frequently report reduced desire for highly palatable (calorie-dense) foods specifically, beyond general appetite reduction.

Insulin secretion (glucose-dependent): GLP-1 stimulates insulin secretion only when blood glucose is elevated — this glucose-dependence means the mechanism does not cause hypoglycaemia at therapeutic doses in people without diabetes.

The Clinical Evidence: STEP Trials

The STEP (Semaglutide Treatment Effect in People with Obesity) trial programme is the primary evidence base. The key trials:

STEP 1 (2021, New England Journal of Medicine)

1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity), without diabetes, randomised to semaglutide 2.4mg weekly vs placebo, combined with lifestyle intervention (diet + exercise counselling):

• Mean weight loss at 68 weeks: 14.9% (semaglutide) vs 2.4% (placebo)
• ≥5% weight loss: 86.4% vs 31.5%
• ≥10% weight loss: 69.1% vs 12.0%
• ≥15% weight loss: 50.5% vs 4.9%
• ≥20% weight loss: 32.0% vs 1.7%

The magnitude of weight loss in STEP 1 substantially exceeds all previous pharmacological weight loss trials. Approximately one in three participants lost more than 20% of body weight at 68 weeks.

STEP 2 (2021, Lancet)

STEP 2 tested semaglutide in people with type 2 diabetes (n=1,210):

• Mean weight loss: 9.6% (2.4mg) vs 6.2% (1.0mg, the diabetes dose) vs 3.4% (placebo)
• Weight loss in T2D is lower than in non-diabetic populations — likely related to the anabolic effects of higher baseline insulin levels

STEP 4 (2021, JAMA)

STEP 4 examined what happens when semaglutide is discontinued after 20 weeks of treatment:

• Participants who switched to placebo regained approximately two-thirds of their lost weight within 48 weeks
• Participants who continued semaglutide continued losing weight (further 7.9%)

The discontinuation data is clinically critical: Weight regain after stopping semaglutide is substantial and rapid, reflecting the fact that the medication is treating a chronic condition (obesity), not curing it. This mirrors what happens with other chronic disease medications — stopping antihypertensives returns blood pressure to pre-treatment levels.

SELECT Trial (2023, New England Journal of Medicine)

SELECT examined cardiovascular outcomes with semaglutide 2.4mg in adults with overweight/obesity and established cardiovascular disease (no diabetes):

• 20% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke)
• This cardiovascular benefit was independent of weight loss magnitude

SELECT established semaglutide as a cardiovascular medication in its own right, not merely a weight management tool, and influenced NICE approval considerations.

Side Effects: What Clinical Trials Show

Gastrointestinal side effects are the most common adverse effects, driven by the gastric emptying slowing mechanism:

Common (>10% of participants in trials):

• Nausea: 44% (vs 16% placebo) — most prominent during dose escalation
• Diarrhoea: 30% (vs 16% placebo)
• Vomiting: 24% (vs 6% placebo)
• Constipation: 24% (vs 11% placebo)

Most GI side effects are dose-dependent and transient:

• Symptoms are most prominent during the dose escalation phase (4-week increments from 0.25mg to 2.4mg)
• Most patients habituate to the final dose — a 2021 analysis found that 83% of participants completing STEP 1 were still on full dose at week 68
• Taking semaglutide with food (a small amount before injection) reduces nausea for many patients

Discontinued due to adverse events: 7% in STEP 1 (vs 3.1% placebo) — meaning the large majority of participants tolerated the treatment to completion.

Less common but significant:

• Acute pancreatitis: Reported in approximately 0.3% of semaglutide users in trials; classified as a rare adverse event. People with a history of pancreatitis should discuss this risk with their prescriber
• Gallbladder events: Gallstones and cholecystitis are increased with rapid weight loss by any mechanism; semaglutide may marginally increase this risk beyond weight-loss-related gallstone risk
• Diabetic retinopathy (in T2D patients): Reported in some T2D trials — likely related to rapid glucose normalisation rather than a direct semaglutide effect; relevant only for people with T2D and pre-existing retinopathy
• Lean mass loss: STEP trials measured body composition in subgroups — approximately 40% of total weight lost was lean tissue, which is higher than desirable. This underscores the importance of resistance training and high protein intake during semaglutide therapy

UK Prescribing: Who Is Eligible

NICE guidance (TA875, 2023) recommends Wegovy (semaglutide 2.4mg) for adults with:

• BMI ≥35 kg/m² and at least one weight-related comorbidity (T2D, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease), OR
• BMI 30–34.9 with at least one comorbidity and meeting additional criteria
• As a 2-year prescribing course (not indefinite open-ended prescribing under initial NICE guidance)
• In conjunction with a reduced-calorie diet and increased physical activity

Access pathways:

• NHS: Through specialist weight management services (Tier 3); waiting lists are common
• Private prescription: Available through registered UK online prescribers (e.g., Numan, eMed, private GPs) — typically £200–280/month; same clinical eligibility criteria apply
• Pharmacy supply: Wegovy is available in UK pharmacies with a valid prescription

Not appropriate for:

• Pregnancy or breastfeeding
• Personal or family history of medullary thyroid carcinoma or MEN2
• Active eating disorders
• Severe gastrointestinal disease
• People with active pancreatitis

Maximising Outcomes on Semaglutide

Clinical trial participants received lifestyle counselling alongside medication — the weight loss figures from STEP trials reflect this combined approach.

Protein and Resistance Training Are Critical

The lean mass loss finding (approximately 40% of weight loss being lean tissue in some analyses) is a significant concern. This is substantially mitigated by:

• Protein intake: 1.6–2.0g/kg body weight per day provides the amino acid substrate for lean mass preservation
• Resistance training: 3 sessions/week with progressive overload is the primary stimulus for lean mass maintenance during calorie deficit
• Combined effect: A 2023 study (Obesity) found that semaglutide users who performed resistance training preserved significantly more lean mass than those doing aerobic exercise only or no exercise

Semaglutide reduces appetite effectively but does not direct which tissues are metabolised. Without adequate protein and resistance training, the calorie deficit occurs through a combination of fat and lean tissue loss.

Managing Nausea During Dose Escalation

Practical strategies for the escalation phase (typically 16–20 weeks):

• Eat a small amount of food before or with the weekly injection
• Avoid high-fat, spicy, or very large meals in the 24 hours following injection
• Stay well hydrated
• If nausea is severe, delay dose escalation (common medical practice — not all patients reach 2.4mg; many achieve good results at lower maintenance doses)

Understanding Weight Loss Trajectory

Weight loss on semaglutide is not linear and the rate changes over the treatment period:

• Weeks 0–16 (escalation phase): Weight loss begins immediately but may be slower during dose escalation as the therapeutic dose is being established
• Weeks 16–48: Maximum rate of loss, typically 0.5–1 kg/week as appetite suppression at full dose is most pronounced
• Weeks 48+: Rate of loss typically slows; weight may plateau; this is normal — a plateau at a significantly lower weight than the starting weight is still a treatment success
• Maintenance: Weight maintenance at reduced body weight is the goal; this may require continued medication

Long-Term Planning

Given the STEP 4 evidence for weight regain on discontinuation, people starting semaglutide should discuss long-term plans with their prescriber before starting:

• Is this a 2-year course with planned discontinuation (per initial NICE guidance) with lifestyle habits established to maintain weight?
• Is longer-term continuation planned?
• What monitoring (HbA1c, blood pressure, lipids) will be done to track metabolic improvements?

Comparison with Other Approved Treatments

Semaglutide represents a step-change over older pharmacological options. Tirzepatide (dual GIP/GLP-1 agonist, Mounjaro) produces even greater weight loss in clinical trials, though both are similarly approved through the same NICE eligibility criteria.

Conclusion

Semaglutide 2.4mg weekly (Wegovy) produces approximately 15% body weight loss at 68 weeks in clinical trials — roughly half of participants lose more than 15% and a third lose more than 20%. The STEP 1 and SELECT trials establish both the weight loss efficacy and cardiovascular outcome benefits. Side effects are predominantly gastrointestinal and most pronounced during dose escalation. Discontinuation leads to substantial weight regain in most people, reflecting obesity's nature as a chronic, relapsing condition requiring ongoing management. UK eligibility requires BMI ≥35 with comorbidities through NICE criteria. Maximising outcomes requires consistent resistance training and protein intake at 1.6–2.0g/kg/day to preserve lean mass — the medication creates the appetite reduction and calorie deficit; diet quality and exercise determine what proportion of the weight lost is fat versus muscle.

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Semaglutide is a prescription medication requiring medical assessment and monitoring. Consult a GP or specialist prescriber to determine whether semaglutide is clinically appropriate for you.